Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 24, 2013 Phillip Broadwith	US sues Novartis over alleged kickbacks Novartis has used illegal payments to induce pharmacies to switch kidney transplant patients onto its immunosuppressant drug Myfortic (mycophenolate sodium), a US government lawsuit alleges.
InternetNews December 15, 2004 Tim Gray	Time Warner Settles Fraud Case Time Warner said today that it has agreed to pay $210 million in criminal and civil fines to settle a federal fraud case stemming from allegedly shady advertising deals within its America Online division.
Pharmaceutical Executive May 1, 2005 Robert Ullmann	Back Page: Unhealthy Justice More than any other healthcare law, the Medicare/Medicaid exclusion statute has distorted our criminal justice system with government fraud investigations. This well-intentioned but misguided law should be repealed.
InternetNews October 13, 2005 Roy Mark	Price-Fixing Costs Samsung $300M The Korean chip giant is latest DRAM maker to plead guilty in US courts to its role in a global price-fixing conspiracy. The size of the fine is historic in proportion. Infineon and Hynix had already plead guilty to similar charges.
Chemistry World June 10, 2014 Anthony King	Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US.
InternetNews November 16, 2006 David Needle	Another Guilty Plea in DRAM Price Fixing Scandal The U.S. Department of Justice announced today that a former executive of Elpida Memory, a large Japanese manufacturer of DRAM chips, agreed to plead guilty for his participation in a global conspiracy to fix prices.
The Motley Fool December 26, 2006 Brian Lawler	Bristol-Myers in the Giving Spirit The pharmaceutical finally settled with the U.S. DOJ and various state attorneys general over allegations that it was artificially inflating stated wholesale drug prices in order to gouge consumers and government health-care programs. What does it mean to investors?
Chemistry World November 19, 2012 Andrew Turley	BP to pay 4.5 billion for disaster Oil super major BP has agreed to pay $4 billion in fines and penalties and plead guilty to criminal charges for the 2010 Deepwater Horizon disaster, which killed 11 people and spilled millions of barrels of oil into the Gulf of Mexico.
InternetNews December 21, 2006 David Needle	Samsung Exec Pleads Guilty in DRAM Probe Prison time for Young Hwan Park in computer memory price-fixing case.
InternetNews December 2, 2004 Michael Singer	Infineon Execs Plead Guilty to Price-Fixing Four Infineon executives agreed to plead guilty to charges they conspired to fix prices in the computer memory sector, officials said Thursday.
InternetNews April 21, 2005 Roy Mark	Hynix Cops Guilty Plea in DRAM Debacle Korean chipmaker agrees to third-largest criminal antitrust fine in U.S. history in RAM chips price-fixing conspiracy.
InternetNews October 19, 2006 Roy Mark	More Indictments in DRAM Price-Fixing Probe Two former Samsung officials and a former Hynix executive are the latest to be charged in the Department of Justice's ongoing investigation into a DRAM chip price-fixing conspiracy.
Chemistry World January 20, 2010 Phil Taylor	Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year.
InternetNews August 4, 2010	HP, DoJ Reach Deal to Settle Kickback Case Without admitting guilt, the computing giant has reached a settlement with authorities at the Department of Justice to resolve allegations that it provided kickbacks to win government contracts.
InternetNews November 26, 2008 Richard Adhikari	ID Thieves Hit Federal Credit Unions, Consumers Sophisticated crooks are charged with filching funds from credit unions for the Senate, Navy and State Department while stealing millions from consumers' home equity lines of credit.
InternetNews August 16, 2007 Roy Mark	IBM, PWC Settle Kickback Charges IBM and PriceWaterhouseCoopers agreed today to pay $5.9 million to settle allegations that the companies made illegal kickbacks to obtain government technology contracts.
InternetNews December 1, 2005 Roy Mark	Samsung Pleads Guilty to Price Fixing Korean electronics giant Samsung agrees to pay second-largest criminal antitrust fine in U.S. history.
Pharmaceutical Executive September 1, 2006 Patrick Clinton	From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
The Motley Fool November 16, 2007 David Lee Smith	Busy Chevron's Lighter Pockets Chevron has agreed to pay $30 million relating to charges that, earlier in the decade, it paid kickbacks to the Iraqi government of Saddam Hussein.
The Motley Fool December 17, 2004 Bill Mann	AOL: Is Half a Billion Enough? Time Warner pays big to settle fraud charges against its problem child, AOL. As for the current management at Time Warner, they profess to want to conclude things with regulators so that they can once again tap the equity market for currency for acquisitions and other capital needs.
BusinessWeek January 12, 2004	Egg On Enron Faces The people who brought about the Enron debacle are slowly starting to pay for their crimes.
The Motley Fool January 31, 2007 Brian Lawler	Warner Chilcott's Healthy Guidance The specialty drugmaker may be new to the public markets, but it's far from a risky proposition.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Searcher June 2012 Stephanie C. Ardito	The Medical Digital: How Safe Are the Prescription Drugs we Take? Monitoring Adverse Events and Recalls For general information about prescription and clinical trial drugs, the following websites have been around for a while and have excellent reputations.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool October 22, 2007 Brian Lawler	No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
CFO April 1, 2003 Kris Frieswick	Fraud Squad Federal investigators are on a crusade to elevate corporate misdeeds to criminal offenses.
Pharmaceutical Executive November 1, 2008	No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
InternetNews February 4, 2005 Tim Gray	Time Warner Sails on Strong 2004 Ad sales helped the company's quarterly profit stay healthy all year.
BusinessWeek January 12, 2004	On Trial This year, the wheels of justice may catch up to some corporate movers and shakers.
Chemistry World November 24, 2015 Phillip Broadwith	Toeing the advertising line When it comes to advertising pharmaceuticals, companies have to tread a little more carefully.
The Motley Fool March 18, 2004 Brian Gorman	The Drug Cost Conundrum While drug prices continue to climb, the public and its representatives in government are demanding cheaper pharmaceuticals. The industry is not likely to find cover in Medicare biotechnology. Instead, investors should look for drug makers that are finding ways to operate leaner and meaner.
InternetNews May 24, 2005 Tim Gray	Time Warner Considered Selling Off AOL Time Warner would consider spinning-off America Online in the future to help finance new acquisitions.
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
The Motley Fool July 17, 2006 Stephen D. Simpson	Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
InternetNews April 13, 2004 Colin C. Haley	Report: SEC to Charge TW Over AOL Ad Deal A probe over the ISP's accounting for $400 million in questionable ad revenue will reportedly culminate in a formal charge for AOL parent Time Warner this summer.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.